Aurinia Pharmaceuticals Inc (AUPH)

traders view logo Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

Aurinia Pharmaceuticals Inc (AUPH) Profile

Aurinia Pharmaceuticals Inc (AUPH.xnas) is a late-stage clinical biopharmaceutical company headquartered in Victoria, British Columbia, Canada. Aurinia is developing and commercialising therapies to treat targeted patient populations with serious diseases with high unmet medical needs. The company employs 294 people, has a US commercial hub in Rockville and Maryland, and extends to other global areas. The Aurinia Pharmaceuticals Inc stock is listed on the NASDAQ and had a market capitalisation of $2.41B (USD) as of January 2022. In December 2020, Aurinia Pharmaceuticals and Otsuka Pharmaceuticals entered a collaboration and licensing agreement to develop and commercial oral voclosporin as a treatment for Lupus nephritis (LN) in the European Union, Japan, United Kingdom, and Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein, and Ukraine. Aurinia Pharmaceuticals announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS (voclosporin) for the treatment of adults with active lupus nephritis. The LUPKYNIS is the first and only approved medicine from FDA with 3 years of pivotal trial results, including long-term safety data, within LN.

Holding cost
Long
-5%
Short
-2.5%
Trading hours in US Eastern Time
Fri
16:30-23:00
Mon
16:30-23:00
Tue
16:30-23:00
Wed
16:30-23:00
Thu
16:30-23:00
Sun
Closed
Sat
Closed

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

Why Trade Aurinia Pharmaceuticals Inc (AUPH.xnas) with FP Markets? An Australian-regulated forex & CFD broker
go long or short
Go Long or Short

Increase your ability to profit in
all market conditions
Leverage options up to 20:1

direct market access
Direct Market Access (DMA) Execution

Real-time, transparent share prices
Control, Functionality and deep liquidity
Full Market depth & see your orders in the queue

advanced platforms
Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with
superior client portal

24/5 Multilingual customer support
24/5 Multilingual
Customer Support

Award winning support &
personal account managers

global exposure
Global Exposure

Low margins and competitive commission
+10,000 products on global stocks
across 4 continents

earn dividends
Earn Dividends

On long positions
No ownership of physical
shares necessary

Bắt đầu với nhà môi giới được Australia Quản lý

bullet Truy cập trên 10.000 công cụ tài chính
bullet Tự động mở & đóng vị thế
bullet Lịch sự kiện tin tức & kinh tế
bullet Chỉ báo & biểu đồ kỹ thuật
bullet Bao gồm nhiều công cụ hơn

Bằng việc cung cấp email của mình, bạn đồng ý với chính sách về quyền riêng tư của FP Markets và nhận các tài liệu marketing trong tương lai từ FP Markets. Bạn có thể hủy đăng ký bất cứ lúc nào.




Source - database | Page ID - 17047

Get instant Updates in Telegram